MX2019002918A - Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. - Google Patents
Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.Info
- Publication number
- MX2019002918A MX2019002918A MX2019002918A MX2019002918A MX2019002918A MX 2019002918 A MX2019002918 A MX 2019002918A MX 2019002918 A MX2019002918 A MX 2019002918A MX 2019002918 A MX2019002918 A MX 2019002918A MX 2019002918 A MX2019002918 A MX 2019002918A
- Authority
- MX
- Mexico
- Prior art keywords
- activation system
- contact activation
- diseases associated
- metabolite biomarkers
- biomarkers
- Prior art date
Links
- 230000004913 activation Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 239000002207 metabolite Substances 0.000 title 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Computational Biology (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395770P | 2016-09-16 | 2016-09-16 | |
| US201762518367P | 2017-06-12 | 2017-06-12 | |
| PCT/US2017/051755 WO2018053247A1 (en) | 2016-09-16 | 2017-09-15 | Metabolite biomarkers for diseases associated with the contact activation system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002918A true MX2019002918A (es) | 2019-07-18 |
Family
ID=59974882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002918A MX2019002918A (es) | 2016-09-16 | 2017-09-15 | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
| MX2024004195A MX2024004195A (es) | 2016-09-16 | 2019-03-13 | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004195A MX2024004195A (es) | 2016-09-16 | 2019-03-13 | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11340237B2 (https=) |
| EP (1) | EP3513197A1 (https=) |
| JP (4) | JP7225090B2 (https=) |
| KR (3) | KR102464380B1 (https=) |
| CN (2) | CN117169508A (https=) |
| AU (2) | AU2017325986B2 (https=) |
| CA (1) | CA3037157A1 (https=) |
| CO (1) | CO2019002607A2 (https=) |
| IL (2) | IL265199B2 (https=) |
| MX (2) | MX2019002918A (https=) |
| NZ (1) | NZ792393A (https=) |
| WO (1) | WO2018053247A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| IL265195B2 (en) | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| US11340237B2 (en) | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| CA3144694A1 (en) | 2019-07-25 | 2021-01-28 | Jose A. Horcajadas | Identification of viable human embryos |
| CN110514772A (zh) * | 2019-08-09 | 2019-11-29 | 中国医学科学院基础医学研究所 | 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用 |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| US20230174674A1 (en) * | 2020-04-04 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113495137A (zh) * | 2021-06-29 | 2021-10-12 | 江苏省中医院 | 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用 |
| CN117310059B (zh) * | 2023-11-30 | 2024-02-02 | 中国人民解放军总医院 | 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995021601A2 (en) | 1994-01-11 | 1995-08-17 | Protein Engineering Corporation | Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| EP1711828A2 (en) | 2004-01-28 | 2006-10-18 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2) |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| CA2625744A1 (en) | 2005-10-11 | 2007-04-19 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2008016883A2 (en) * | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| WO2008019052A2 (en) | 2006-08-03 | 2008-02-14 | Numira Biosciences, Inc. | Methods and compositions for identifying biomarkers |
| WO2008046511A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Crtac as a biomarker, therapeutic and diagnostic target |
| WO2008046509A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Ltbp2 as a biomarker, therapeutic and diagnostic target |
| WO2008046528A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Npr3 as a biomarker, therapeutic and diagnostic target |
| WO2008046508A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Tgfb2 as a biomarker, therapeutic and diagnostic target |
| EP2087359A1 (en) | 2006-10-16 | 2009-08-12 | Bayer Schering Pharma AG | Prss23 as a biomarker, therapeutic and diagnostic target |
| WO2008046510A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Fn1 as a biomarker, therapeutic and diagnostic target |
| ES2383235T3 (es) | 2006-10-16 | 2012-06-19 | Bayer Pharma Aktiengesellschaft | CTGF como biomarcador , diana terapéutica y diagnóstica |
| FR2914066B1 (fr) * | 2007-03-20 | 2009-05-22 | Polyintell Sarl | Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant |
| JP5564491B2 (ja) * | 2008-04-29 | 2014-07-30 | サイケメディクス コーポレイション | 固相多分析物アッセイ法 |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
| DK2466312T3 (da) * | 2009-08-12 | 2020-01-13 | Human Metabolome Tech Inc | Phosphoethanolamine som biomarkør for depression |
| WO2011051805A1 (en) | 2009-10-27 | 2011-05-05 | Anaxomics Biotech Sl | Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data |
| PH12012500850A1 (en) * | 2009-10-30 | 2013-01-07 | Prometheus Laboratories Inc | Methods for diagnosing irritable bowel syndrome |
| US9494605B2 (en) * | 2009-11-20 | 2016-11-15 | Pharnext | Diagnostic tools for charcot-marie-tooth disease |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| EP2550533A4 (en) | 2010-03-23 | 2014-01-08 | Purdue Research Foundation | EARLY RECOGNITION OF RECYCLING BREAST CANCER BY METABOLIT PROFILING |
| US20120040383A1 (en) | 2010-08-12 | 2012-02-16 | Wei Jia | Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| JP5986440B2 (ja) | 2012-07-05 | 2016-09-06 | 国立医薬品食品衛生研究所長 | アルツハイマー病の発症を予測する方法 |
| WO2014036182A2 (en) | 2012-08-29 | 2014-03-06 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| US20140086825A1 (en) * | 2012-09-24 | 2014-03-27 | William J. McFaul | Methods and kits for assessing, modulating and treating substances affecting bodily processes |
| US10690670B2 (en) | 2013-01-20 | 2020-06-23 | Dyax Corp. | Assays for determining levels of plasma protease C1 inhibitor |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| WO2014159637A1 (en) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
| US9127024B2 (en) * | 2013-03-15 | 2015-09-08 | Intrexon Corporation | Boron-containing diacylhydrazines |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| EP2884282A1 (en) * | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| EP3805756A1 (en) | 2014-04-08 | 2021-04-14 | Metabolon, Inc. | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment |
| US20170343557A1 (en) | 2014-09-22 | 2017-11-30 | Kenneth Kun-Yu WU | Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| JP6907188B2 (ja) | 2015-08-13 | 2021-07-21 | ダイアックス コーポレーション | 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 |
| JP6570472B2 (ja) | 2016-03-30 | 2019-09-04 | 株式会社マンダム | 毛髪の損傷の評価方法 |
| EA201990730A1 (ru) | 2016-09-16 | 2019-08-30 | Дайэкс Корп. | Рнк-биомаркеры для наследственного ангионевротического отека |
| IL265195B2 (en) | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| US11340237B2 (en) | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
-
2017
- 2017-09-15 US US16/333,101 patent/US11340237B2/en active Active
- 2017-09-15 IL IL265199A patent/IL265199B2/en unknown
- 2017-09-15 KR KR1020197010802A patent/KR102464380B1/ko active Active
- 2017-09-15 EP EP17777137.5A patent/EP3513197A1/en active Pending
- 2017-09-15 KR KR1020257006143A patent/KR20250030022A/ko active Pending
- 2017-09-15 CN CN202310782203.XA patent/CN117169508A/zh active Pending
- 2017-09-15 IL IL314752A patent/IL314752A/en unknown
- 2017-09-15 CA CA3037157A patent/CA3037157A1/en active Pending
- 2017-09-15 CN CN201780057052.4A patent/CN109716137B/zh active Active
- 2017-09-15 WO PCT/US2017/051755 patent/WO2018053247A1/en not_active Ceased
- 2017-09-15 MX MX2019002918A patent/MX2019002918A/es unknown
- 2017-09-15 AU AU2017325986A patent/AU2017325986B2/en active Active
- 2017-09-15 KR KR1020227038426A patent/KR102775437B1/ko active Active
- 2017-09-15 NZ NZ792393A patent/NZ792393A/en unknown
- 2017-09-15 JP JP2019514825A patent/JP7225090B2/ja active Active
-
2019
- 2019-03-13 MX MX2024004195A patent/MX2024004195A/es unknown
- 2019-03-21 CO CONC2019/0002607A patent/CO2019002607A2/es unknown
-
2022
- 2022-04-25 US US17/728,285 patent/US12188948B2/en active Active
-
2023
- 2023-02-08 JP JP2023017898A patent/JP7451791B2/ja active Active
-
2024
- 2024-01-30 AU AU2024200561A patent/AU2024200561B2/en active Active
- 2024-03-06 JP JP2024034012A patent/JP7692508B2/ja active Active
- 2024-11-26 US US18/960,119 patent/US20250199014A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092519A patent/JP2025124816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002918A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
| CO2019002608A2 (es) | Biomarcadores de arn para angioedema hereditario | |
| GB2556004A (en) | Markers of stroke and stroke severity | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| CL2017001940A1 (es) | Dispositivo de medición de la calidad del suelo | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2021001659A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| CL2019003286A1 (es) | Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos. | |
| MX2017015011A (es) | Ensayo a base de celulas para detectar homodimeros anti-cd3. | |
| BR112013024190A2 (pt) | microdispositivo para detectar ou tratar doença e métodos para fabricar microdispositivo e para detectar doença em indivíduo em necessidade do mesmo | |
| BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| AR053948A1 (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
| MX2016004167A (es) | Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal. | |
| BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| MX2022014741A (es) | Metodos para detectar bordetella. | |
| CO2019006234A2 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal | |
| BR112018010764A2 (pt) | método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente | |
| UY38393A (es) | Anticuerpos contra bcma soluble | |
| CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto | |
| MX2022002886A (es) | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. | |
| MX2015015015A (es) | Metodo para diagnosticar cancer. |